Association of adenomyosis and different endometriosis localizations to pain symptoms and their response to hormone therapy

In: BMC Women's Health · 2026 · doi:10.1186/s12905-026-04967-1 · W7220847441
Observational OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-10 ⓘ

This study found that pain intensity and hormonal therapy response in adenomyosis and endometriosis depend on specific lesion localizations, with superficial endometriosis linked to more severe symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-10 · read from full text ⓘ

This retrospective study evaluated the relationship between pain intensity and specific lesion localizations in 234 women diagnosed with adenomyosis and various forms of endometriosis. Researchers utilized visual analogue scales to assess symptoms such as menstrual pain, dyspareunia, and dyschezia, while also analyzing treatment responses to progestin-only or estro-progestin therapies among a subset of patients. The findings indicated that superficial endometriosis was independently associated with more intense pain across multiple categories, whereas deep infiltrating endometriosis showed varied associations depending on the anatomical site, and lesion multiplicity did not significantly correlate with symptom severity. This paper is centrally about endometriosis and adenomyosis, specifically examining how different anatomical presentations influence clinical pain profiles and hormonal treatment outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

To evaluate whether the intensity of pain symptoms in women with adenomyosis and endometriosis is associated with the specific lesion localizations or with disease extension. A retrospective investigation was performed on 234 women with sonographic diagnosis of adenomyosis and endometriosis (cases), of whom 174 (74.4%) had adenomyosis, 89 (38.0%) superficial endometriosis, 103 (44.0%) ovarian endometriosis, and 131 (56.0%) deep infiltrating endometriosis (DIE) of the utero-sacral ligaments (USL; n = 76), rectum ( n = 61), parametrium ( n = 46), and vesical-uterine folder ( n = 13); 75 control women were also enrolled. Menstrual and intermenstrual pain, deep dyspareunia, dysuria, dyschezia, and low back pain were rated on a visual analogue scale (VAS). The modification of each symptom with therapy was evaluated in the 123 women receiving progestin-only (P; n = 81) or estro-progestin (EP; n = 42) treatment, also comparing P versus EP. Concomitant lesions were more frequent (78.6%) than single localizations (21.4%). Superficial endometriosis was independently associated with more intense menstrual pain (median difference 2.62, 95% CI 1.10–4.15), deep dyspareunia (median difference 1.91, 95%CI 0.09–3.74), and low back pain (median difference 2.03, 95%CI 0.06–3.99), and with higher odds of dyschezia (OR 2.44, 95%CI 1.01–5.89). Ovarian endometriosis was associated with more intense menstrual pain (median difference1.93, 95%CI 0.63–3.24) but with less intense intermenstrual pain (median difference − 2.30, 95%CI -3.89 to -0.71) and deep dyspareunia (median difference − 3.17, 95%CI -4.97 to -1.38). DIE of the USL was associated with lower odds of dyschezia (OR 0.36, 95%CI 0.14–0.92), whereas adenomyosis and DIE of the rectum or parametrium were not independently associated with any pain symptom. The response to therapy did not differ among localizations for most symptoms: women with ovarian endometriosis had higher odds of a smaller-than-average reduction of intermenstrual pain (OR 3.04, 95%CI 1.12–8.26), and women with DIE of the parametrium of deep dyspareunia (OR 5.31, 95%CI 1.02–27.60). A poorer response of deep dyspareunia was observed in women receiving P than EP (OR 4.03, 95%CI 1.49–10.92). At baseline all symptoms were more intense in cases than in controls except dysuria; at follow-up they remained higher except for menstrual pain and dysuria. The intensity of pain and its response to hormonal therapy were associated with the specific lesion localizations, rather than with the number of concomitant lesions. Superficial endometriosis appears to be the localization associated with more intense pain symptoms.
Full text 5,527 characters · extracted from oa-html · 5 sections · click to expand

Abstract

Background To evaluate whether the intensity of pain symptoms in women with adenomyosis and endometriosis is associated with the specific lesion localizations or with disease extension.

Methods

A retrospective investigation was performed on 234 women with sonographic diagnosis of adenomyosis and endometriosis (cases), of whom 174 (74.4%) had adenomyosis, 89 (38.0%) superficial endometriosis, 103 (44.0%) ovarian endometriosis, and 131 (56.0%) deep infiltrating endometriosis (DIE) of the utero-sacral ligaments (USL; n = 76), rectum (n = 61), parametrium (n = 46), and vesical-uterine folder (n = 13); 75 control women were also enrolled. Menstrual and intermenstrual pain, deep dyspareunia, dysuria, dyschezia, and low back pain were rated on a visual analogue scale (VAS). The modification of each symptom with therapy was evaluated in the 123 women receiving progestin-only (P; n = 81) or estro-progestin (EP; n = 42) treatment, also comparing P versus EP.

Results

Concomitant lesions were more frequent (78.6%) than single localizations (21.4%). Superficial endometriosis was independently associated with more intense menstrual pain (median difference 2.62, 95% CI 1.10–4.15), deep dyspareunia (median difference 1.91, 95%CI 0.09–3.74), and low back pain (median difference 2.03, 95%CI 0.06–3.99), and with higher odds of dyschezia (OR 2.44, 95%CI 1.01–5.89). Ovarian endometriosis was associated with more intense menstrual pain (median difference1.93, 95%CI 0.63–3.24) but with less intense intermenstrual pain (median difference − 2.30, 95%CI -3.89 to -0.71) and deep dyspareunia (median difference − 3.17, 95%CI -4.97 to -1.38). DIE of the USL was associated with lower odds of dyschezia (OR 0.36, 95%CI 0.14–0.92), whereas adenomyosis and DIE of the rectum or parametrium were not independently associated with any pain symptom. The response to therapy did not differ among localizations for most symptoms: women with ovarian endometriosis had higher odds of a smaller-than-average reduction of intermenstrual pain (OR 3.04, 95%CI 1.12–8.26), and women with DIE of the parametrium of deep dyspareunia (OR 5.31, 95%CI 1.02–27.60). A poorer response of deep dyspareunia was observed in women receiving P than EP (OR 4.03, 95%CI 1.49–10.92). At baseline all symptoms were more intense in cases than in controls except dysuria; at follow-up they remained higher except for menstrual pain and dysuria.

Conclusions

The intensity of pain and its response to hormonal therapy were associated with the specific lesion localizations, rather than with the number of concomitant lesions. Superficial endometriosis appears to be the localization associated with more intense pain symptoms. Similar content being viewed by others Abbreviations - BMI: - Body mass index - CER: - Regional Ethics Committee - CI: - Confidence interval - CR: - Coefficient of regression - DIE: - Deep infiltrating endometriosis - EP: - Estro-progestins - IDEA: - International Deep Endometriosis Analysis - MUSA: - Morphological Uterus Sonographic Assessment - P: - Progestins - SD: - Standard deviation - USL: - Utero sacral ligaments - VAS: - Visual analogue scale

Acknowledgements

We would like to thank all the sanitary personnel for their help in patient management. Funding This study received no funding. Author information Authors and Affiliations Corresponding author Ethics declarations Ethics approval and consent to participate The study was approved by the local ethics committee. Studies performed in our hospital are approved by the ethics committee of the Regione Liguria. The study was approved with the number CER Liguria 305/2022-DB id 12401). All procedures were performed according to the guidelines of good clinical practice as specified in the Declaration of Helsinki. At enrolment, each woman signed an informed consent to participate in the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Additional information Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. About this article Cite this article Xholli, A., Costantino, A., Primizia, E. et al. Association of adenomyosis and different endometriosis localizations to pain symptoms and their response to hormone therapy. BMC Women's Health (2026). https://doi.org/10.1186/s12905-026-04967-1 Received: Accepted: Published: DOI: https://doi.org/10.1186/s12905-026-04967-1

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-10-11T06:05:52.046646+00:00
License: CC0 · commercial use OK